1 / 11

SEISMIC Trial

SEISMIC Trial. The Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell) using an Injection Catheter Trial. SEISMIC Trial. SEISMIC Trial. Presented at ACC / i2 2008 in Chicago Presented by Dr. Patrick W. Serruys.

qamar
Download Presentation

SEISMIC Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SEISMIC Trial The Safetyand Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell) using an Injection Catheter Trial

  2. SEISMIC Trial SEISMIC Trial Presented at ACC / i2 2008 in Chicago Presented by Dr. Patrick W. Serruys Copyleft Clinical Trial Results. You Must Redistribute Slides

  3. SEISMIC Trial: Background • Evaluated the safety and efficacy of injecting patient’s own skeletal muscle cells into scarred myocardium using a needle-tipped catheter. • Skeletal muscle cells have been shown to be superior to other muscle cell types in pre-clinical studies¹. ¹ E. Meliga, HJ Duckers, R Spencer, PW Serruys. Rationale and interim analysis data from the SEISMIC study. EuroIntervention Supplement (2007) 2 B84-B88. Presented at SCAI/ACC i2 08 Summit

  4. SEISMIC Trial: Study Design 47 patients with congestive heart failure prior to randomization Prospective. Randomized. Multicenter. Mean follow-up 6 months 66% received cell therapy and 34% received optimal medical treatment. R Cell therapy 586 ± 193 x 106 cells n=31 Optimal medical treatment n=16 6 mos. follow-up • Primary Safety Endpoint: Incidence of procedural and device related serious adverse events. • Efficacy Endpoints: Change in global LVEF by MUGA scan, change in NYHA classification of heart failure, distance achieved during 6 minute walk test. Copyleft Clinical Trial Results. You Must Redistribute Slides Presented at SCAI-ACCi2 08 Summit

  5. SEISMIC Trial: Primary Safety Endpoint • There were 15 incidences of sustained arrhythmia in the cell therapy group vs. 14 incidences in the medical treatment control group. Incidence of adverse events Presented at SCAI/ACC i2 08 Summit Copyleft Clinical Trial Results. You Must Redistribute Slides

  6. SEISMIC Trial: Efficacy Endpoint • The cell therapy group was able to walk an additional 60.3 ± 54.1 meters in the 6 minute walk test. • The medical therapy group walked an additional 0.4 ± 185.7 meters in the same test. Copyleft Clinical Trial Results. You Must Redistribute Slides Presented at SCAI/ACC i2 08 Summit

  7. SEISMIC Trial: Efficacy Endpoint cont. NYHA HF status deterioration (%) NYHA HF status improvement (%) n =5 n =1 n =3 n =1 Medical treatment Cell therapy Medical treatment Cell therapy Copyleft Clinical Trial Results. You Must Redistribute Slides Presented at SCAI-ACC i2 Summit

  8. SEISMIC Trial: Efficacy Endpoint at 6 months • Global ejection fraction was higher in the medical treatment group compared to the cell therapy group after 6 month follow-up. Global EF (%) Presented at SCAI-ACC i2 08 Summit Copyleft Clinical Trial Results. You Must Redistribute Slides

  9. SEISMIC Trial: Efficacy Endpoint at 6 months 54.5±7.1mm End Systolic LV diameter (mm) 39.4±2.7mm Copyleft Clinical Trial Results. You Must Redistribute Slides Presented at SCAI/ACC i2 08 Summit

  10. SEISMIC Trial: Limitations • Future trials may consider including a larger sample size to appropriately power the study. Presented at SCAI/ACC i2 08 Summit

  11. SEISMIC Trial: Summary • Autologous myoblast implantation in patients with congestive heart failure is feasible. • Myoblast implantation may improve symptoms of heart failure. • There was no significant effect in ventricular thickness or LV ejection fraction between the cell therapy group and the medical treatment group at 6 months. Presented at SCAI/ACC i2 08 Summit

More Related